Imperial College
Ergon has forged a close collaboration with Dr. Jacques Behmoaras at the Imperial College London in order to develop small organic molecule therapies for macrophage-driven diseases.
Following a successful first phase during which investigators from Ergon, Imperial, and Queen Mary University of London (QMUL) discovered a way to reduce inflammation in autoimmune diseases by taking advantage of metabolic pathways of pro-inflammatory macrophages, Ergon and Imperial plan to expand their collaboration to include development of drug candidates based on targets identified through a systems biology approach in Dr. Behmoaras’ lab.
ADDITIONAL COLLABORATIONS WITH: